Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can tiny needles regrow hair? new study aims to find out

NCT ID NCT07580521

Symptom relief Sponsor: Taipei Medical University WanFang Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Aug 21, 2026 · Updated 1 time

Summary

This study tests whether microneedling can improve hair growth in people with mild to moderate pattern baldness. About 25 adults will receive microneedling on one side of their scalp every two weeks for six sessions, while the other side gets no treatment. Researchers will measure hair density, thickness, and growth over 24 weeks to see if the treatment works.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 25 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jun 2026

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

22 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients aged ≥22 years * Mild to moderate androgenic alopecia (for males, Norwood's grading II-IV, and for females, Ludwig stage I-II.) Exclusion Criteria: * Presence of obvious scalp wounds or other dermatologic lesions, including papulopustular rosacea, stage III-IV acne, eczema, herpes simplex, warts, scleroderma, bacterial or fungal infections, open wounds, actinic keratosis, or skin cancer * Alopecia other than androgenetic alopecia * Unilateral or uneven hair loss * History of keloid formation or keloid tendency * Pregnant women * Patients with HIV infection * Coagulation abnormalities (international normalized ratio \[INR\] \> 1.2, activated partial thromboplastin time \[aPTT\] \> 40 seconds), thrombocytopenia (\< 100,000/μL), hemophilia, or current use of antiplatelet or anticoagulant medications * Patients with hepatitis B, hepatitis C, acquired immunodeficiency, or cancer * Patients using a cardiac pacemaker or other similar implantable medical devices * Patients using extracorporeal membrane oxygenation (ECMO) or other types of life-support equipment * Patients using medical devices with electrocardiographic monitoring functions

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Androgenic alopecia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

alopecia androgenetic alopecia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Androgenic alopecia

Contacts and locations

Locations

  • Wang Fang Hospital

    Taipei, Taiwan

More trials for these conditions

Other studies related to the condition(s) this trial covers.